Academic-Industry CollaborationTerry J. OpgenorthTerry J. Opgenorth

Abbott LaboratoriesAbbott Laboratories

The Development of Endothelin Receptor Antagonists for the Treatment of Prostate Cancer

Lessons for Career Development

Career Preparation for Industry

• search Out presentations/abstracts from biotech and pharma companies

• read pharmacology journals

• correspond with authors – request compounds– Proposal – mutual benefit => “collaborate”

1996: Atrasentan publication

54 publications(18 Abbott-only authors)

Nelson Lab15 pubs/6 with Abbott

Bagnatto Lab15 pubs/3 with Abbott

1995: Bagnatto LabET mitogenic/cancer

1995 (Dec): Candidate Declared 1995: J. Nelson

Prostate Cancer Hypothesis

1993-4: Lepor Lab3 pubs - Prostate

To 1995: 30 publications(24 Abbott-only authors)

1990: 2 Abbott ET

publications

1988: Discovery of Endothelin

Abbott ET Project Begins

ACADEMIA ACADEMIAINDUSTRY

Wall Street Journal – May 14, 2001

“An Abbott VP happened to be in the audience and soon got Dr. Nelson together with Abbott researchers working on the endothelin program…”

“…a compound in search of disease….We were planning to bring if forward as a cardiovascular agent”

J. Clin. Oncol. 21: 679-689, 2003

Abbott & Hopkins researchers are primary authors

Nat. Rev. Cancer 3: 110-116, 2003

Abbott

Rome

Laval U.

U. Pitt.

Physiologists in Pharma and Biotech Research

Physiologist•Molecular•Cell•Organ•Animal

Pharmacologist

•Molecular•Cell•Organ•Animal

IntegrativeSystems

Drug Discovery

Drug

DRC

Career Preparation for Industry

• search Out presentations/abstracts from biotech and pharma companies

• read pharmacology journals

• correspond with authors – request compounds– Proposal – mutual benefit => “collaborate”